Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:108164.
doi: 10.5402/2012/108164. Epub 2012 Jul 8.

Microemulsion drug delivery system: for bioavailability enhancement of ampelopsin

Affiliations

Microemulsion drug delivery system: for bioavailability enhancement of ampelopsin

Shailendra Singh Solanki et al. ISRN Pharm. 2012.

Abstract

Ampelopsin, one of the most common flavonoids, reported to possess numerous pharmacological activities and shows poor aqueous solubility. The purpose of this study was to enhance the dissolution rate and bioavailability of this drug by developing a novel delivery system that is microemulsion (ME) and to study the effect of microemulsion (ME) on the oral bioavailability of ampelopsin. Capmul MCM-based ME formulation with Cremophor EL as surfactant and Transcutol as cosurfactant was developed for oral delivery of ampelopsin. Optimised ME was evaluated for its transparency, viscosity, percentage assay and so forth. Solubilisation capacity of the ME system was also determined. The prepared ME was compared with the pure drug solution and commercially available tablet for in vitro drug release. The optimised ME formulation containing ampelopsin, Capmul MCM (5.5%), Cremophor EL (25%), Transcutol P (8.5%), and distilled water showed higher in vitro drug release, as compared to plain drug suspension and the suspension of commercially available tablet. These results demonstrate the potential use of ME for improving the bioavailability of poor water soluble compounds, such as ampelopsin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of ampelopsin.
Figure 2
Figure 2
Viscosity changes of ME with increasing water content.
Figure 3
Figure 3
Results of the electroconductivity study.
Figure 4
Figure 4
In vitro drug release of drug from microemulsion (ME), commercially Ampelopsin formulation (CAF), and plain drug suspension (PDS).

References

    1. Ye J, Guan Y, Zeng S, Liu D. Ampelopsin prevents apoptosis induced by H2O2 in MT-4 lymphocytes. Planta Medica. 2008;74(3):252–257. - PubMed
    1. TAN GY, ZHANG MH, FENG JH, HAN AY, ZHENG SS, XIE P. Effects of pretreatment by the flavanol ampelopsin on porcine kidney epithelial cell injury induced by hydrogen peroxide. Agricultural Sciences in China. 2010;9(4):598–604.
    1. Qi S, Xin Y, Guo Y, et al. Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-κB signaling pathways. International Immunopharmacology. 2012;12(1):278–287. - PubMed
    1. Kundaković T, Stanojković T, Milenković M, et al. Cytotoxic, antioxidant, and antimicrobial activities of Ampelopsis brevipedunculata and Parthenocissus tricuspidata (Vitaceae) Archives of Biological Sciences. 2008;60(4):641–647.
    1. Ruan LP, Yu BY, Fu GM, Zhu DN. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. Journal of Pharmaceutical and Biomedical Analysis. 2005;38(3):457–464. - PubMed

LinkOut - more resources